文献速递糖尿病

1型糖尿病妊娠晚期C肽再现:胰腺再生还是胎儿高胰岛素血症?

Reappearance of C-Peptide During the Third Trimester of Pregnancy in Type 1 Diabetes: Pancreatic Regeneration or Fetal Hyperinsulinism?
PubMed 文献 · Diabetes Care · 2021-06-26

该研究基于CONCEPTT试验,纵向监测127名1型糖尿病孕妇在12、24、34周的母体C肽及脐血C肽。发现三种C肽轨迹模式,其中24%孕妇在34周首次可检测到C肽,这些孕妇孕中期血糖控制不佳,其新生儿脐血C肽升高且不良结局发生率更高,提示C肽可能来自胎儿而非胰腺再生。

要点

  • 1型糖尿病孕妇孕34周首次出现C肽与孕中期高血糖相关。
  • 该C肽再现模式的新生儿脐血C肽升高,巨大儿和新生儿低血糖风险增加。
  • 结果提示C肽可能从胎儿转移至母体,不支持妊娠相关β细胞再生。

核心结论

  • 1型糖尿病孕妇孕34周首次出现母体C肽与孕中期高血糖、脐血C肽升高及新生儿并发症高发相关,提示C肽胎儿来源而非β细胞再生。

研究设计与样本

  • 基于CONCEPTT试验的纵向队列,纳入127名1型糖尿病孕妇,在孕12、24、34周检测母体血清C肽,并检测脐血C肽。

主要发现

  • 识别出三种母体C肽轨迹:模式1全程不可测(n=74,58%),模式2基线可测(n=22,17%),模式3在34周首次可测(n=31,24%)。
  • 模式3孕妇24周血糖控制欠佳(高于目标范围时间50%),其新生儿脐血C肽几何均值1319 vs 718 pmol/L(P=0.007)。
  • 模式3新生儿巨大儿发生率90% vs 60%(P=0.002),新生儿低血糖42% vs 14%(P=0.001),NICU入住45% vs 23%(P=0.023),均高于模式1。

关键数值与推荐

  • 模式1母体C肽全程<3 pmol/L;模式2基线C肽7-272 pmol/L;模式3在34周C肽4-26 pmol/L。

临床怎么用

  • 对1型糖尿病孕妇孕中期血糖管理需更严格,孕晚期新出现C肽应警惕胎儿高胰岛素血症及新生儿并发症风险。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed longitudinal patterns of maternal C-peptide concentration to examine the hypothesis of β-cell regeneration in pregnancy with type 1 diabetes. RESEARCH DESIGN AND METHODS: C-peptide was measured on maternal serum samples from 127 participants (12, 24, and 34 weeks) and cord blood during the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT). C-peptide was measured using a highly sensitive direct and solid-phase competitive electrochemiluminescent immunoassay. RESULTS: Three discrete patterns of maternal C-peptide trajectory were identified: pattern 1, undetectable throughout pregnancy, n = 74 (58%; maternal C-peptide <3 pmol/L); pattern 2, detectable at baseline, n = 22 (17%; maternal C-peptide 7-272 pmol/L at baseline); and pattern 3, undetectable maternal C-peptide at 12 and 24 weeks, which first became detectable at 34 weeks, n = 31 (24%; maternal C-peptide 4-26 pmol/L at 34 weeks). Baseline characteristics and third trimester glucose profiles of women with pattern 1 and pattern 3 C-peptide trajectories were similar, but women in pattern 3 had suboptimal glycemia (50% time above range) at 24 weeks' gestation. Offspring of women with pattern 3 C-peptide trajectories had elevated cord blood C-peptide (geometric mean 1,319 vs. 718 pmol/L; P = 0.007), increased rates of large for gestational age (90% vs. 60%; P = 0.002), neonatal hypoglycemia (42% vs. 14%; P = 0.001), and neonatal intensive care admission (45% vs. 23%; P = 0.023) compared with pattern 1 offspring. CONCLUSIONS: First maternal C-peptide appearance at 34 weeks was associated with midtrimester hyperglycemia, elevated cord blood C-peptide, and high rates of neonatal complications. This suggests transfer of C-peptide from fetal to maternal serum and is inconsistent with pregnancy-related β-cell regeneration.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Meek CL, Oram RA, McDonald TJ, et al. Reappearance of C-Peptide During the Third Trimester of Pregnancy in Type 1 Diabetes: Pancreatic Regeneration or Fetal Hyperinsulinism? Diabetes Care. 2021. PMID: 34175829. doi:10.2337/dc21-0028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。